JP2021515806A5 - - Google Patents
Info
- Publication number
- JP2021515806A5 JP2021515806A5 JP2020568847A JP2020568847A JP2021515806A5 JP 2021515806 A5 JP2021515806 A5 JP 2021515806A5 JP 2020568847 A JP2020568847 A JP 2020568847A JP 2020568847 A JP2020568847 A JP 2020568847A JP 2021515806 A5 JP2021515806 A5 JP 2021515806A5
- Authority
- JP
- Japan
- Prior art keywords
- binding
- antigen
- binding protein
- protein according
- triple
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862637470P | 2018-03-02 | 2018-03-02 | |
| US62/637,470 | 2018-03-02 | ||
| PCT/EP2019/055207 WO2019166650A1 (en) | 2018-03-02 | 2019-03-01 | Trispecific antigen binding proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021515806A JP2021515806A (ja) | 2021-06-24 |
| JP2021515806A5 true JP2021515806A5 (https=) | 2022-03-09 |
| JPWO2019166650A5 JPWO2019166650A5 (https=) | 2022-03-09 |
Family
ID=65802034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020568847A Pending JP2021515806A (ja) | 2018-03-02 | 2019-03-01 | 三重特異性抗原結合タンパク質 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20200062858A1 (https=) |
| EP (1) | EP3759146A1 (https=) |
| JP (1) | JP2021515806A (https=) |
| KR (1) | KR20210028140A (https=) |
| CN (1) | CN112119099A (https=) |
| AU (1) | AU2019228128A1 (https=) |
| CA (1) | CA3089230A1 (https=) |
| MX (1) | MX2020009116A (https=) |
| WO (1) | WO2019166650A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201792573A1 (ru) | 2015-05-21 | 2018-04-30 | Харпун Терапьютикс, Инк. | Триспецифические связанные белки и способы их применения |
| CN106397592A (zh) * | 2015-07-31 | 2017-02-15 | 苏州康宁杰瑞生物科技有限公司 | 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白 |
| JP7101621B2 (ja) | 2016-05-20 | 2022-07-15 | ハープーン セラピューティクス，インク． | 単一ドメイン血清アルブミン結合タンパク質 |
| HRP20241268T1 (hr) | 2017-10-13 | 2024-12-06 | Harpoon Therapeutics, Inc. | Trispecifični proteini i postupci primjene |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| WO2020061482A1 (en) | 2018-09-21 | 2020-03-26 | Harpoon Therapeutics, Inc. | Egfr binding proteins and methods of use |
| SG11202103022WA (en) | 2018-09-25 | 2021-04-29 | Harpoon Therapeutics Inc | Dll3 binding proteins and methods of use |
| EP3816185A1 (en) * | 2019-11-04 | 2021-05-05 | Numab Therapeutics AG | Multispecific antibody directed against pd-l1 and a tumor-associated antigen |
| EP4055365B1 (en) * | 2019-11-08 | 2026-01-21 | NanoTemper Technologies GmbH | Characterization of particles in solution |
| JP7369297B2 (ja) | 2019-12-17 | 2023-10-25 | ファイザー・インク | Ｃｄ４７、ｐｄ－ｌ１に特異的な抗体、およびその使用 |
| WO2022087211A1 (en) * | 2020-10-22 | 2022-04-28 | Janux Therapeutics, Inc. | Antibodies targeting her2 and cd3 and uses thereof |
| CN114853897B (zh) * | 2021-04-15 | 2024-01-26 | 北京大学深圳研究生院 | 抗cd19/cd22/cd3三特异性抗体及用途 |
| EP4347636A4 (en) * | 2021-06-03 | 2025-04-16 | Harpoon Therapeutics, Inc. | BCMA targeting trispecific proteins and methods of use |
| WO2023043958A1 (en) * | 2021-09-16 | 2023-03-23 | Gt Biopharma, Inc. | Pd-l1 targeting fusion proteins and methods of use thereof |
| CN114371282B (zh) * | 2021-12-30 | 2025-07-11 | 上海药明生物技术有限公司 | 一种评估抗原沉默效应对抗体药效影响的方法及其应用 |
| KR20260049221A (ko) * | 2023-07-29 | 2026-04-13 | 상하이 카이진 바이오테크놀로지, 리미티드 | 변형된 e형 다중특이성 항체 |
| WO2025109119A1 (en) | 2023-11-22 | 2025-05-30 | Priothera Sas | Methods of treatment with multispecific antigen-binding proteins in combination with s1p receptor modulators |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| ES2234241T3 (es) * | 1998-01-23 | 2005-06-16 | Vlaams Interuniversitair Instituut Voor Biotechnologie | Derivados de anticuerpo de multiples fines. |
| CZ302070B6 (cs) | 1998-04-21 | 2010-09-29 | Micromet Ag | Jednoretezcový multifunkcní polypeptid, polynukleotid, vektor obsahující tento polynukleotid, bunka transfekovaná tímto polynukleotidem, prostredek obsahující tento polypeptid, polynukleotid nebo vektor a jejich použití a zpusob identifikace aktiváto |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| EP2014680A1 (en) * | 2007-07-10 | 2009-01-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives |
| EP2406284B9 (en) | 2009-03-10 | 2017-03-01 | Biogen MA Inc. | Anti-bcma antibodies |
| EP3974453A3 (en) | 2010-11-16 | 2022-08-03 | Amgen Inc. | Agents and methods for treating diseases that correlate with bcma expression |
| WO2012158818A2 (en) * | 2011-05-16 | 2012-11-22 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| BR112014004168A2 (pt) | 2011-08-23 | 2017-12-12 | Roche Glycart Ag | anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, célula hospedeira procariótica ou eucariótica, método de produção de anticorpo e invenção |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| JP6636803B2 (ja) | 2013-02-05 | 2020-01-29 | エンクマフ エスアーエールエル | Ｂｃｍａに対する抗体の選択のための方法 |
| TWI716362B (zh) * | 2014-10-14 | 2021-01-21 | 瑞士商諾華公司 | 針對ｐｄ－ｌ１之抗體分子及其用途 |
| BR112017011166A2 (pt) | 2014-11-26 | 2018-02-27 | Xencor, Inc. | anticorpos heterodiméricos que se ligam a cd3 e cd38 |
| EA036379B1 (ru) | 2014-12-12 | 2020-11-02 | Блубёрд Био, Инк. | Химерные антигенные рецепторы к bcma |
| WO2016115274A1 (en) * | 2015-01-14 | 2016-07-21 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| EA201792573A1 (ru) | 2015-05-21 | 2018-04-30 | Харпун Терапьютикс, Инк. | Триспецифические связанные белки и способы их применения |
| EP3165536A1 (en) * | 2015-11-09 | 2017-05-10 | Ludwig-Maximilians-Universität München | Trispecific molecule combining specific tumor targeting and local immune checkpoint inhibition |
| EP3390454B1 (en) | 2015-12-17 | 2026-02-04 | University of Maryland, Baltimore County | A recombinant bi-specific polypeptide for coordinately activating tumor-reactive t-cells and neutralizing immune suppression |
| MA43874A (fr) * | 2016-01-13 | 2018-11-21 | Compass Therapeutics Llc | Constructions de liaison à l'antigène immunomodulateur multispécifique |
| CN116063544A (zh) | 2016-02-03 | 2023-05-05 | 安进研发（慕尼黑）股份有限公司 | Bcma和cd3双特异性t细胞接合抗体构建体 |
| KR20190003938A (ko) | 2016-02-25 | 2019-01-10 | 셀 메디카 스위처란트 아게 | 면역치료를 위한 변형된 세포 |
| WO2017165464A1 (en) * | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| IL262241B2 (en) * | 2016-04-13 | 2024-05-01 | Sanofi Sa | Trispecific and/or trivalent binding proteins with a crossover dual variable domain arm and a traditional antibody fab arm, pharmaceutical composition comprising said binding proteins and their uses in preventing and/or treating cancer or inflammatory diseases |
| WO2017201281A1 (en) | 2016-05-18 | 2017-11-23 | Mayo Foundation For Medical Education And Research | Targeting pd-l1 on tumor cells |
| CN116987189A (zh) | 2016-05-20 | 2023-11-03 | 哈普恩治疗公司 | 单链可变片段cd3结合蛋白质 |
| EP3252078A1 (en) * | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
| EP4282877A3 (en) | 2016-08-10 | 2024-02-21 | Legend Biotech Ireland Limited | Chimeric antigen receptors targeting bcma and methods of use thereof |
| US20190225702A1 (en) | 2016-10-14 | 2019-07-25 | Harpoon Therapeutics, Inc. | Innate immune cell trispecific binding proteins and methods of use |
| EP4295918A3 (en) * | 2016-11-02 | 2024-03-20 | Bristol-Myers Squibb Company | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma |
| EP3645050A4 (en) * | 2017-06-25 | 2021-08-11 | Systimmune, Inc. | Multi-specific antibodies and methods of making and using thereof |
-
2019
- 2019-03-01 AU AU2019228128A patent/AU2019228128A1/en not_active Abandoned
- 2019-03-01 JP JP2020568847A patent/JP2021515806A/ja active Pending
- 2019-03-01 WO PCT/EP2019/055207 patent/WO2019166650A1/en not_active Ceased
- 2019-03-01 KR KR1020207028030A patent/KR20210028140A/ko not_active Ceased
- 2019-03-01 EP EP19711257.6A patent/EP3759146A1/en not_active Withdrawn
- 2019-03-01 MX MX2020009116A patent/MX2020009116A/es unknown
- 2019-03-01 CN CN201980016065.6A patent/CN112119099A/zh active Pending
- 2019-03-01 CA CA3089230A patent/CA3089230A1/en active Pending
- 2019-08-05 US US16/532,295 patent/US20200062858A1/en not_active Abandoned
- 2019-10-04 US US16/593,704 patent/US20200024358A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021515806A5 (https=) | ||
| JPWO2019166650A5 (https=) | ||
| JP2020506971A5 (https=) | ||
| JP2020521448A5 (https=) | ||
| JP2024099850A5 (https=) | ||
| JP2019532619A5 (https=) | ||
| JP2020522473A5 (https=) | ||
| JP2021534096A5 (https=) | ||
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2013545455A5 (https=) | ||
| JP2020063262A5 (https=) | ||
| JP2021508469A5 (https=) | ||
| JP2017504577A5 (https=) | ||
| JP2013527761A5 (https=) | ||
| JP2020114210A5 (https=) | ||
| JP2020510422A5 (https=) | ||
| RU2013142600A (ru) | Белки, связывающие специфический мембранный антиген простаты, и соответствующие композиции и способы | |
| JP2014518615A5 (https=) | ||
| JP2021511811A5 (https=) | ||
| JP2018523493A5 (https=) | ||
| JP2020522474A5 (https=) | ||
| RU2015144098A (ru) | Четырехвалентные биспецифические антитела | |
| JP2020510659A5 (https=) | ||
| JP2021522347A5 (https=) | ||
| JP2021533796A5 (https=) |